AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PARADIGM BIOPHARMACEUTICALS

0.275

-0.015-5.17%

Volume:881.66K

Turnover:245.41K

Market Cap:107.09M

PE:-6.05

High:0.295

Open:0.295

Low:0.267

Close:0.290

Loading ...

Overview Company News Filings

Is Paradigm Biopharmaceuticals (ASX:PAR) In A Good Position To Invest In Growth?

Simply Wall St.

BRIEF-Paradigm Biopharmaceuticals Posts HY Net Loss Attributable A$5.9 Million

Paradigm Biopharmaceuticals Ltd - Hy Net Loss Attributable a$5.9 Mln

THOMSON REUTERS

Paradigm Biopharmaceuticals Secures Ethics Committee Approval for Phase Three Knee Osteoarthritis Clinical Trial

MT Newswires Live

Paradigm Biopharmaceuticals Selects Clinical Research Organization for Osteoarthritis Trial; Shares Up 4%

MT Newswires Live

3 ASX healthcare stocks soaring on positive company updates

PAR Technology to Offer $100 Million Convertible Senior Notes due 2030

MT Newswires Live

Why these small cap ASX shares could deliver very big returns in 2025

3 ASX Penny Stocks With Market Caps Under A$300M To Consider

Simply Wall St.

PAR Technology Acquires Delaget for $132 Million

MT Newswires Live

6 ASX All Ords shares lifted to 'strong buy' consensus ratings for the new year

BUZZ-Australia's Paradigm Biopharma falls on discounted placement

Paradigm Biopharmaceuticals to Raise AU$16 Million via Share Placement; Shares Down 6%

MT Newswires Live

BRIEF-Paradigm Biopharmaceuticals Announces A$16M Placement

Global Lithium Resources And 2 Other ASX Penny Stocks To Consider

Simply Wall St.

Why is this ASX healthcare stock crashing 26% today?

Paradigm Biopharmaceuticals Ltd-Par Capital Raising Presentation

THOMSON REUTERS

Paradigm Biopharmaceuticals Ltd - Placement to Fund Global Phase 3 Clinical Trial Setup and Other Strategic Initiatives

THOMSON REUTERS

Paradigm Biopharmaceuticals - a$16M Placement at a$0.40 per Share

THOMSON REUTERS

These small cap ASX shares could surge 27% to 38% higher

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PAR.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PAR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","market":"AU","secType":"STK","nameCN":"PARADIGM BIOPHARMACEUTICALS","latestPrice":0.275,"timestamp":1745302320000,"preClose":0.29,"halted":0,"volume":881664,"delay":0,"nameEN":"PARADIGM BIOPHARMACEUTICALS","floatShares":345063923,"shares":389428823,"eps":-0.045455,"marketStatus":"Closed","change":-0.015,"latestTime":"04-22 16:12:00 AEST","open":0.295,"high":0.295,"low":0.267,"amount":245408,"amplitude":0.096552,"askPrice":0.275,"askSize":73291,"bidPrice":0.27,"bidSize":117800,"shortable":3,"etf":0,"ttmEps":-0.045455,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.29,"openAndCloseTimeList":[[1745280000000,1745301600000]],"volumeRatio":0.936074,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","floatShares":345063923,"roa":"-33.14%","roe":"-42.91%","lyrEps":-0.199988,"volumeRatio":0.936074,"shares":389428823,"dividePrice":0,"high":0.295,"amplitude":0.096552,"preClose":0.29,"low":0.267,"week52Low":0.132,"pbRate":"3.14","psRate":"6412.75","week52High":0.66,"institutionHeld":0,"latestPrice":0.275,"committee":0.23292,"eps":-0.045455,"divideRate":0,"volume":881664,"delay":0,"ttmEps":-0.045455,"open":0.295,"prevYearClose":0.3,"prevWeekClose":0.29,"prevMonthClose":0.33,"prevQuarterClose":0.33,"fiveDayClose":0.29,"twentyDayClose":0.42,"sixtyDayClose":0.352},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PAR.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2523364696","title":"Is Paradigm Biopharmaceuticals (ASX:PAR) In A Good Position To Invest In Growth?","url":"https://stock-news.laohu8.com/highlight/detail?id=2523364696","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523364696?lang=en_us&edition=fundamental","pubTime":"2025-03-30 08:04","pubTimestamp":1743293068,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.So should Paradigm Biopharmaceuticals  shareholders be worried about its cash burn?For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth . The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/paradigm-biopharmaceuticals-asx-par-good-000428047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7508","PAR.AU","PAR","BK7067","BK4157"],"gpt_icon":0},{"id":"2514365711","title":"BRIEF-Paradigm Biopharmaceuticals Posts HY Net Loss Attributable A$5.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514365711","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514365711?lang=en_us&edition=fundamental","pubTime":"2025-02-28 09:33","pubTimestamp":1740706428,"startTime":"0","endTime":"0","summary":"BRIEF-Paradigm Biopharmaceuticals Posts HY Net Loss Attributable A$5.9 MillionFeb 28 (Reuters) - Paradigm Biopharmaceuticals Ltd PAR.AX:HY NET LOSS ATTRIBUTABLE A$5.9 MILLIONFurther company coverage: PAR.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI28T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","PAR.AU","BK7508"],"gpt_icon":0},{"id":"2514358884","title":"Paradigm Biopharmaceuticals Ltd - Hy Net Loss Attributable a$5.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514358884","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514358884?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:14","pubTimestamp":1740690858,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI28T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","PAR.AU"],"gpt_icon":0},{"id":"2513266798","title":"Paradigm Biopharmaceuticals Secures Ethics Committee Approval for Phase Three Knee Osteoarthritis Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2513266798","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513266798?lang=en_us&edition=fundamental","pubTime":"2025-02-24 10:02","pubTimestamp":1740362534,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  received centralized Human Research Ethics Committee approval in Australia for its pivotal PARA_OA_012 phase three clinical trial, which will study the safety and efficacy of injectable pentosan polysulfate sodium for the treatment of knee osteoarthritis, according to a Monday Australian bourse filing.It said the recruitment of the first subject for the trial is on target and first participant dosing is expected in the second quarter, the filing said.The approval allows the trial to proceed across multiple key clinical trial sites in Australia, the filing said.The first trial sites to be activated are expected to be located in Victoria.The firm's shares rose 2% in early trading on Monday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","XKO.AU","XJO.AU","PAR.AU","BK7508","XAO.AU"],"gpt_icon":0},{"id":"2507977983","title":"Paradigm Biopharmaceuticals Selects Clinical Research Organization for Osteoarthritis Trial; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507977983","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507977983?lang=en_us&edition=fundamental","pubTime":"2025-01-31 09:33","pubTimestamp":1738287219,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  selected Advanced Clinical as its preferred partner for a phase 3 clinical trial evaluating the dose and treatment effect of injectable pentosan polysulfate sodium in knee osteoarthritis pain, according to a Friday filing with the Australian bourse.The company expects to receive centralized ethics approval for Australia soon, with the first sites to be activated in Victoria and up to 10 sites across the country, per the filing. The dosing of the first participant is anticipated in the second quarter of the year.Paradigm Biopharmaceuticals shares rose nearly 4% in midday trade Friday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","XAO.AU","PAR.AU","BK7508","XJO.AU","BK7067"],"gpt_icon":0},{"id":"2505888802","title":"3 ASX healthcare stocks soaring on positive company updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2505888802","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505888802?lang=en_us&edition=fundamental","pubTime":"2025-01-24 12:08","pubTimestamp":1737691713,"startTime":"0","endTime":"0","summary":"ASX healthcare stocks are in the green on Friday, with the S&P/ASX 200 Health Care Index (ASX: XHJ) 0.41% higher while the benchmark S&P/ASX 200 Index (ASX: XJO) is up 0.32%. Here are three of the bes","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/24/3-asx-healthcare-stocks-soaring-on-positive-company-updates/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7503","PPS.AU","PAR.AU","BK7094","BK7067","BK7007","XAO.AU","XJO.AU","PPS","BK7508","BK7016","SOM.AU","XKO.AU","4DX.AU"],"gpt_icon":0},{"id":"2505272594","title":"PAR Technology to Offer $100 Million Convertible Senior Notes due 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2505272594","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505272594?lang=en_us&edition=fundamental","pubTime":"2025-01-21 23:08","pubTimestamp":1737472115,"startTime":"0","endTime":"0","summary":"PAR Technology  said Tuesday it plans to offer $100 million total principal amount of convertible senior notes due 2030 in a private offering.The company also intends to provide the initial purchaser a 13-day option to buy up to an additional $15 million of notes.PAR said it plans to use the net proceeds from the offering for the full repayment of its $90 million principal amount outstanding of the term loan under its credit deal with Blue Owl Capital , and the remaining net proceeds for general corporate purposes.The notes will not be redeemed before Jan. 20, 2028, at the company's discretion, it said.Shares of PAR were down 6.4% in recent Tuesday trading.Price: 68.55, Change: -4.65, Percent Change: -6.35","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK4157","OBDC","PAR","BK7508","PAR.AU","BK4135"],"gpt_icon":0},{"id":"2501379359","title":"Why these small cap ASX shares could deliver very big returns in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501379359","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501379359?lang=en_us&edition=fundamental","pubTime":"2025-01-08 11:17","pubTimestamp":1736306236,"startTime":"0","endTime":"0","summary":"Investors with a high risk tolerance may want to take a look at the small cap ASX shares in this article. That's because they have just been named as buys and tipped to rise materially from current le","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/08/why-these-small-cap-asx-shares-could-deliver-very-big-returns-in-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7503","BK7508","PPS","RDY.AU","PAR.AU","BK7016","BK7067","PPS.AU"],"gpt_icon":0},{"id":"2501821874","title":"3 ASX Penny Stocks With Market Caps Under A$300M To Consider","url":"https://stock-news.laohu8.com/highlight/detail?id=2501821874","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501821874?lang=en_us&edition=fundamental","pubTime":"2025-01-07 09:05","pubTimestamp":1736211903,"startTime":"0","endTime":"0","summary":"The ASX 200 index is poised to open higher, marking a potential fourth consecutive day of gains, despite challenges in the iron ore sector and mixed signals from global markets. In such a fluctuating market landscape, investors may find opportunities in lesser-known stocks that offer unique value propositions. Penny stocks, often representing smaller or newer companies with strong financial foundations, can present intriguing investment opportunities.Magontec Limited, with a market cap of A$17.52 million, has announced a significant share buyback program, aiming to repurchase up to 28.48% of its issued share capital, pending shareholder approval. Despite being unprofitable and reporting a net loss of A$7.47 million for the first nine months of 2024, the company maintains strong liquidity with short-term assets far exceeding liabilities and debt well covered by operating cash flow. The management team is experienced with an average tenure of 8.8 years, and while volatility remains high,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-asx-penny-stocks-market-010503907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7067","XKO.AU","HLO.AU","XJO.AU","EVO.AU","BK7164","SKS.AU","BK7055","BK7114","MGL.AU","ANG.AU","BK7132","BK7077","VLS.AU","BRI.AU","SHA.AU","SRV.AU","XAO.AU","NGI.AU","BK7096","BK7133","BK7070","BK7062","BK7023","LBL.AU","BK7095","BK7508","PAR.AU","BK7088"],"gpt_icon":0},{"id":"2500923232","title":"PAR Technology Acquires Delaget for $132 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2500923232","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500923232?lang=en_us&edition=fundamental","pubTime":"2025-01-02 20:53","pubTimestamp":1735822427,"startTime":"0","endTime":"0","summary":"PAR Technology (PAR) said Thursday it acquired Delaget, a restaurant analytics and business intelligence solutions provider, in a deal valued at $132 million.The company said the transaction, which closed on Dec. 31, was paid primarily in shares of its common stock.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","PAR.AU","BK7508","PAR","BK4157"],"gpt_icon":0},{"id":"2500558950","title":"6 ASX All Ords shares lifted to 'strong buy' consensus ratings for the new year","url":"https://stock-news.laohu8.com/highlight/detail?id=2500558950","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500558950?lang=en_us&edition=fundamental","pubTime":"2025-01-02 07:56","pubTimestamp":1735775773,"startTime":"0","endTime":"0","summary":"S&P/ASX All Ords (ASX: XAO) shares fell 3.2% in December in an unusually weak final month of the year. Meantime, some brokers changed their ratings on various ASX stocks before heading off on holidays","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/02/6-asx-all-ords-shares-lifted-to-strong-buy-consensus-ratings-for-the-new-year/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["PPS.AU","XAO.AU","BK7508","BK7503","BK7160","TLS.AU","BK7124","PPS","PAR.AU","IDX.AU","BK7070","CBO.AU","BK7067","BK7141","BK7042","BK7511","LFG.AU","HLO.AU","BK7123","INTEU","BK7016"],"gpt_icon":0},{"id":"2490779169","title":"BUZZ-Australia's Paradigm Biopharma falls on discounted placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2490779169","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490779169?lang=en_us&edition=fundamental","pubTime":"2024-12-09 11:50","pubTimestamp":1733716223,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Paradigm Biopharma falls on discounted placement** Shares of Paradigm Biopharmaceuticals PAR.AX fall as much as 25.9% to A$0.430, their lowest levels since Nov  26** The drug development firm announces A$16 mln  placement to institutional and sophisticated investors** Issue price of A$0.40 represents a discount of 31% to last close on Dec 4 when trading was halted pending capital raising announcement** Funds to support global Phase III trials for osteoarthritis treatment with iPPS, beginning in Australia and expanding to key U.S. sites** Objective of Phase III trials include demonstration of improvement in pain and function with subcutaneous injections of pentosan polysulfate sodium   ** Stock has risen 27.1%, YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nL4N3NA062:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","PAR.AU"],"gpt_icon":0},{"id":"2490479681","title":"Paradigm Biopharmaceuticals to Raise AU$16 Million via Share Placement; Shares Down 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490479681","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490479681?lang=en_us&edition=fundamental","pubTime":"2024-12-09 11:04","pubTimestamp":1733713494,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  received firm commitments to raise AU$16 million via the placement of 40 million shares at AU$0.40 apiece, according to a Monday filing with the Australian bourse.The company also plans to issue one listed option for every four shares held under its loyalty option incentive program, exercisable at AU$0.65 and with a 12-month expiry, the filing said.Proceeds will be used to fund a third phase clinical trial for osteoarthritis treatment using pentosan polysulfate sodium injections, starting in Australia in the first quarter of 2025 and expanding to US sites in the second quarter, according to the filing.Shares fell 6% in afternoon trade Monday.Price : $0.55, Change: $-0.04, Percent Change: -6.03%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0994945656.USD","PAR.AU","XAO.AU","BK4125","LU0426412945.USD","XJO.AU","LU0426417589.USD","LU1043141123.HKD","LU0345774631.USD","AUD","XKO.AU","BK7067","BK7508","LU2238339852.HKD"],"gpt_icon":0},{"id":"2490764572","title":"BRIEF-Paradigm Biopharmaceuticals Announces A$16M Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2490764572","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490764572?lang=en_us&edition=fundamental","pubTime":"2024-12-09 09:08","pubTimestamp":1733706503,"startTime":"0","endTime":"0","summary":"BRIEF-Paradigm Biopharmaceuticals Announces A$16M Placement Dec 9  - Paradigm Biopharmaceuticals Ltd PAR.AX:A$16M PLACEMENT AT A$0.40 PER SHAREPLACEMENT TO FUND GLOBAL PHASE 3 CLINICAL TRIAL SETUP AND OTHER STRATEGIC INITIATIVESFurther company coverage: PAR.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nFWN3N800G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","PAR.AU","BK7067"],"gpt_icon":0},{"id":"2490767301","title":"Global Lithium Resources And 2 Other ASX Penny Stocks To Consider","url":"https://stock-news.laohu8.com/highlight/detail?id=2490767301","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490767301?lang=en_us&edition=fundamental","pubTime":"2024-12-09 09:04","pubTimestamp":1733706288,"startTime":"0","endTime":"0","summary":"As the Australian market braces for the Reserve Bank of Australia's latest rate decision, investors are keeping a close eye on potential shifts in economic policy. Amidst these broader market dynamics, penny stocks remain an intriguing investment area, offering affordability and growth potential through smaller or newer companies. Despite being considered an outdated term by some, penny stocks continue to hold relevance as they can provide opportunities for significant returns when backed by strong financials.Click here to see the full list of 1,046 stocks from our ASX Penny Stocks screener.Overview: Global Lithium Resources Limited focuses on the evaluation, exploration, and development of lithium resources in Australia with a market cap of A$58.63 million.Assess Global Lithium Resources' future earnings estimates with our detailed growth reports.ASX:GL1 Financial Position Analysis as at Dec 2024. Overview: Joyce Corporation Ltd  is an Australian company that retails kitchen and wardr","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/hHa1.rnFIozE8uk1FxFmIg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/7a92075e7c274cfc915511d1e9d413e3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/hHa1.rnFIozE8uk1FxFmIg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/7a92075e7c274cfc915511d1e9d413e3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/global-lithium-resources-2-other-010448364.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["GL1.AU","BK7507","XAO.AU","SRV.AU","BK7132","BK7062","BK7508","JYC.AU","MXI.AU","VLS.AU","BK7504","XKO.AU","PAR.AU","BK7095","XJO.AU","BK7164","NGI.AU","BK7070","PLS.AU","SHA.AU","BK7107","BK7096","BK7077","BK7067","ANG.AU","EVO.AU","BK7088","BRI.AU","LBL.AU","BK7055","HLO.AU","BK7114","BK7133"],"gpt_icon":0},{"id":"2490764849","title":"Why is this ASX healthcare stock crashing 26% today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2490764849","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490764849?lang=en_us&edition=fundamental","pubTime":"2024-12-09 07:40","pubTimestamp":1733701255,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals Ltd  shares are starting the week deep in the red. In morning trade, the ASX healthcare stock is down 26% to 43 cents. Why is this ASX healthcare stock crashing deep into the red?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/09/why-is-this-asx-healthcare-stock-crashing-26-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["PAR.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2490750029","title":"Paradigm Biopharmaceuticals Ltd-Par Capital Raising Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2490750029","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490750029?lang=en_us&edition=fundamental","pubTime":"2024-12-09 06:25","pubTimestamp":1733696739,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241208:nTUE1R8WJV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PAR.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2490763750","title":"Paradigm Biopharmaceuticals Ltd -  Placement to Fund Global Phase 3 Clinical Trial Setup and Other Strategic Initiatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2490763750","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490763750?lang=en_us&edition=fundamental","pubTime":"2024-12-09 06:22","pubTimestamp":1733696544,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241208:nFWN3N800G:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PAR.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2490075075","title":"Paradigm Biopharmaceuticals -  a$16M Placement at a$0.40 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2490075075","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490075075?lang=en_us&edition=fundamental","pubTime":"2024-12-09 06:22","pubTimestamp":1733696544,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241208:nFWN3N800G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PAR.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2489272653","title":"These small cap ASX shares could surge 27% to 38% higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2489272653","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489272653?lang=en_us&edition=fundamental","pubTime":"2024-12-08 06:22","pubTimestamp":1733610120,"startTime":"0","endTime":"0","summary":"Investors that have a high tolerance for risk might want to consider the small cap ASX shares in this article. That's because they have just been named as buys with major upside potential. Here's what","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/08/these-small-cap-asx-shares-could-surge-27-to-38-higher/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7064","PPS","PAR.AU","BK7067","BK7503","PPS.AU","BK7508","BK7016","AIM.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":30,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PAR.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-02-06","symbol":"PAR.AU","defaultRemindTime":1738796400000,"type":"split","dateTimestamp":1738760400000,"forFactor":4,"toFactor":5,"ratio":0.8},{"market":"AU","date":"2022-08-17","symbol":"PAR.AU","defaultRemindTime":1660694400000,"type":"split","dateTimestamp":1660658400000,"forFactor":992772,"toFactor":1000000,"ratio":0.992772}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PAR.AU\",market:\"AU\",,,undefined,":[]}}